Mark Clemons

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata et al. · The Lancet Oncology · 2017 · 539 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

Christine Simmons, Naomi Miller, William R. Geddie et al. · Annals of Oncology · 2009 · 288 citations · Full text

Medicine, Oncology, Pathology +17

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Susan Ellard, Mark Clemons, Karen A. Gelmon et al. · Journal of Clinical Oncology · 2009 · 261 citations

Medicine, Oncology, Pharmacology +16

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

George Dranitsaris, Alex Molassiotis, Mark Clemons et al. · Annals of Oncology · 2017 · 229 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Palliative Treatment of Painful Bone Metastases with MR Imaging–guided Focused Ultrasound

David Gianfelice, Gupta Chander, Walter Kucharczyk et al. · Radiology · 2008 · 222 citations

Medicine, Oncology, Radiology +17